Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape?
In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Known as Drug-resistant epilepsy (DRE) or refractory epilepsy, it is a form of epilepsy that is defined as a failure of adequate trials of 2 tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom. It can possibly be a cause of wrong diagnosis, wrong medication, or triggers that can give rise to...
